发明授权
- 专利标题： 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
-
申请号： US16071298申请日： 2017-01-20
-
公开(公告)号： US11001569B2公开(公告)日： 2021-05-11
- 发明人: Ian Stansfield , Olivier Alexis Georges Querolle , Gerhard Max Gross , Edgar Jacoby , Lieven Meerpoel , Janusz Jozef Kulagowski , Calum Macleod , Samuel Edward Mann , Simon Richard Green , George Hynd
- 申请人： Janssen Pharmaceutica NV
- 申请人地址： BE Beerse
- 专利权人： Janssen Pharmaceutica NV
- 当前专利权人： Janssen Pharmaceutica NV
- 当前专利权人地址： BE Beerse
- 优先权： EP16152414 20160122,EP16152415 20160122,EP16159658 20160310,EP16159659 20160310
- 国际申请： PCT/EP2017/051160 WO 20170120
- 国际公布： WO2017/125534 WO 20170727
- 主分类号： C07D401/14
- IPC分类号： C07D401/14 ; C07D403/14 ; C07D405/14 ; C07D413/14 ; A61P35/00
摘要：
The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
信息查询
